Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Interest Income

Income earned on cash, deposits, and investments held by the company.

Kura Oncology, Inc.NASDAQ: KURA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $5.83M fell 26.1% year over year, behind the -2.7% change in trailing-twelve-month interest income. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at +84.6% a year.

Context

  • Interest income amounted to 39.7% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -26.1% toward the trailing-twelve-month pace of -2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.83M+2.5% QoQ
Last fiscal yearDec 2025
$26.77M+17.2% YoY
LTMMar 2026
$24.72M-2.7% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.1%——
1 year+17.2%——
3-year CAGR+84.6%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
26.77M USD
Year-over-year change
+17.2%
4-year CAGR
+117.1%

Interest Income vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 interest income of $24.72M is the 2nd highest of the 11 companies compared; the peer median is $8.1M.
  • Its year-over-year change of -2.7% is the 6th highest of 11, against a peer median of -1.4%.
  • Interest income amounts to 34.5% of revenue for KURA, versus a peer median of 7.5%.
KURA Competitors Peer median
Interest Income for KURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCMHUTCHMED (China) LimitedLTM Jun 2025$37.21M +3.6%+73.4%6.2%
KURAKura Oncology, Inc.LTM Mar 2026$24.72M -2.7%+84.6%34.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$24.38M -6.3%+57.0%11.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$18.56M -20.1%+84.3%2.6%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$13.89M +53.3%——
TYRATyra Biosciences, Inc.LTM Mar 2026$11.81M -31.7%+52.0%—
VSTMVerastem, Inc.LTM Mar 2026$4.4M +17.7%+49.6%8.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$4.3M +105.5%+75.2%1.4%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$3.68M +270.3%+64.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M -18.5%+25.2%508.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 -100.0%——
Peer median (excluding KURA) $8.1M-1.4%+60.8%7.5%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00053.88M67.48M
Cost of Revenue00849K057K
Gross Profit00(849K)53.88M67.43M
Gross Margin———100.0%99.9%
Research & Development84.72M92.81M115.24M169.97M251.07M
Selling, General & Admin46.54M47.05M50.57M77.11M119.98M
Operating Expenses131.26M139.87M164.96M247.08M371.06M
Depreciation & Amortization558K759K849K848K1.03M
EBITDA(129.49M)(134.85M)(150.23M)(169.5M)(275.83M)
EBITDA Margin———-314.6%-408.7%
Operating Income(131.26M)(139.87M)(165.8M)(193.2M)(303.63M)
Operating Margin———-358.5%-449.9%
Interest Income1.21M4.25M14.72M22.85M26.77M
Interest Expense414K229K1.55M1.62M1.51M
Other Income / Expenses792K4.03M13.17M21.23M25.26M
Income Before Tax(130.47M)(135.84M)(152.63M)(171.97M)(278.37M)
Pre-Tax Margin———-319.1%-412.5%
Income Tax Expense0002.02M297K
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Net Margin———-322.9%-412.9%
EPS (Basic)(1.97)(2.03)(2.08)(2.02)(3.18)
EPS (Diluted)(1.97)(2.03)(2.08)(2.02)(3.18)
Weighted Avg Shares66.35M66.99M73.23M86.16M87.68M
Weighted Avg Shares (Diluted)66.35M66.99M73.23M86.16M87.68M

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.